#	Pagina
attuale pagina	/open-h2020/projects/219098/index.html
-1	/open-fp7/projects/85365/index.html

Opendata, web and dolomites

IMPACCT SIGNED

Improved Patient Care by Combinatorial Treatment

Total Cost €

EC-Contrib. €

Partnership

Views

IMPACCT project word cloud

Explore the words cloud of the IMPACCT project. It provides you a very rough idea of what is the project "IMPACCT" about.

patients downstream inhibitors more discovered generates locally poor treatment regulation overexpressed combinatorial diagnostic chromatin cells disciplinary prove correlates expression proliferation gene patient prognosis companion breast avenue poly hope atp medicine forefront basic polymerase effort nudix5 enzyme options repair risk combined nucleus combining cancer parp1 pharmaceutical targeted economic collaborative basis precision ribose 3d structure international conjunction diagnostics care pivotal adp

Project "IMPACCT" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO CENTRE DE REGULACIO GENOMICA Organization address address: CARRER DOCTOR AIGUADER 88 city: BARCELONA postcode: 8003 website: www.crg.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	145˙000 €
EC max contribution	145˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2018-PoC
Funding Scheme	ERC-POC
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2020-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACIO CENTRE DE REGULACIO GENOMICA FUNDACIO CENTRE DE REGULACIO GENOMICA Organization address address: CARRER DOCTOR AIGUADER 88 city: BARCELONA postcode: 8003 website: www.crg.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	145˙000.00

Map

Project objective

Targeted precision medicine combined with companion diagnostics will provide the basis for future more effective more economic patient care. Recent advances in breast cancer treatment combining inhibitors of poly-ADP-ribose polymerase (PARP1) in conjunction with other targets are at the forefront of this new advance both at the level of basic research and pharmaceutical interest, due to its pivotal role in gene expression, chromatin and repair. We have discovered a key enzyme downstream of PARP1 which generates ATP locally in the nucleus; NUDIX5. This enzyme is overexpressed in cancer and correlates with poor prognosis, as the activity of this enzyme is essential for changes within the 3D chromatin structure, gene regulation and the proliferation of cancer cells. We have developed inhibitors of NUDIX5 in addition to a companion diagnostic, and propose to prove using a multi-disciplinary, international collaborative effort that they can be used to determine not only patient risk and treatment options but also provide an exciting new avenue for the combinatorial treatment of breast and (we hope) other cancer patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPACCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPACCT" are provided by the European Opendata Portal: CORDIS opendata.